Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1097140

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1097140

Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2022 - 2030

PUBLISHED:
PAGES: 145 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Biosimulation Market Growth & Trends:

The global biosimulation market size is expected to reach USD 9.95 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.9% from 2022 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Biosimulation Market Report Highlights:

  • By product, software dominated the market in 2021. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and targets drug identification
  • The drug development application segment accounted for the largest revenue share of more than 55.0% in 2021
  • By end-use, pharmaceutical and biotechnology companies held the largest revenue share in 2021 due to the increasing strategic initiatives
  • North America grabbed the largest revenue share of over 45.0% in 2021. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure are expected to drive the regional market over the forecast period
  • The Asia Pacific region is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure
Product Code: GVR-1-68038-051-4

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 segment scope
    • 1.1.2 regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
  • 1.7 List of Secondary Sources
  • 1.8 Objectives
    • 1.8.1 Objective 1
    • 1.8.2 Objective 2
    • 1.8.3 Objective 3
    • 1.8.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Biosimulation Market Summary

Chapter 3 Biosimulation Market Variables, Trends & Scope

  • 3.1 Biosimulation Market Segmentation and Scope
  • 3.2 Biosimulation Market Dynamics
    • 3.2.1 Market driver analysis
    • 3.2.2 Impact analysis
      • 3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic Modeling in the regulatory approval process of drugs
      • 3.2.2.2 Growing number of relapse cases due to increasing drug resistance
      • 3.2.2.3 Rising Technological advancements
      • 3.2.2.4 Increasing need to reduce drug discovery and development costs
      • 3.2.2.5 accelerating formulation development and saving costly studies
      • 3.2.2.6 Increasing investments in the life sciences industry
      • 3.2.2.7 Increasing use of personalized medicine
    • 3.2.3 Market restraint analysis
    • 3.2.4 Impact analysis
      • 3.2.4.1 Lack of standardization
      • 3.2.4.2 Shortage of skilled professionals
      • 3.2.4.3 Intellectual property protection and public policy issues
  • 3.3 Penetration and Growth Prospect Mapping, 2021
  • 3.4 Pricing Analysis
  • 3.5 Biosimulation Market Analysis Tools: Porters
    • 3.5.1 bargaining power of Suppliers: Low
    • 3.5.2 bargaining power of Buyers: Moderate
    • 3.5.3 Therat of Substitutes: Low
    • 3.5.4 Threat of New Entrants: High
    • 3.5.5 Competitive Rivalry: High
  • 3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological)
    • 3.6.1 Political/Legal Landscape
    • 3.6.2 Economic Landscape
    • 3.6.3 Technology Landscape

Chapter 4 Biosimulation Market: Impact of COVID-19

  • 4.1 Impact of Covid-19 on the Biosimulation Market
    • 4.1.1 Current And Future Impact Analysis
    • 4.1.2 Impact of covid-19 on market players
    • 4.1.3 Disease Prevalence Analysis

Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2017 - 2030 (USD Million)

  • 5.1 Definition and Scope
  • 5.2 Product Market Share Analysis, 2021 & 2030
  • 5.3 Biosimulation Market, by Product, 2017 - 2030
  • 5.4 Software
    • 5.4.1 software market, 2017 - 2030 (USD Million)
  • 5.5 Services
    • 5.5.1 Services market, 2017 - 2030 (USD Million)
    • 5.5.2 In-house Services
      • 5.5.2.1 In-house Services market, 2017 - 2030 (USD Million)
    • 5.5.3 Contract Services
      • 5.5.3.1 Contract Services market, 2017 - 2030 (USD Million)

Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2017 - 2030 (USD Million)

  • 6.1 Definition and Scope
  • 6.2 Application Market Share Analysis, 2021 & 2030
  • 6.3 Biosimulation Market, by Application, 2017 - 2030
  • 6.4 Drug Development
    • 6.4.1 drug development market, 2017 - 2030 (USD Million)
  • 6.5 Drug Discovery
    • 6.5.1 Drug Discovery market, 2017 - 2030 (USD Million)
  • 6.6 Others
    • 6.6.1 Others market, 2017 - 2030 (USD Million)

Chapter 7 Biosimulation Market: Segment Analysis, By End-use, 2017 - 2030 (USD Million)

  • 7.1 Definition and Scope
  • 7.2 End-use Market Share Analysis, 2021 & 2030
  • 7.3 Global Biosimulation Market, by End-use, 2017 - 2030
  • 7.4 Pharmaceutical & Biotechnology Companies
    • 7.4.1 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
  • 7.5 CROs
    • 7.5.1 CROs market, 2017 - 2030 (USD million)
  • 7.6 Regulatory Authorities
    • 7.6.1 Regulatory authorities market, 2017 - 2030 (USD Million)
  • 7.7 Academic Research Institutions
    • 7.7.1 Academic research institutions market, 2017 - 2030 (USD million)

Chapter 8 Biosimulation Market: Regional Market Analysis 2017 - 2030 (USD Million)

  • 8.1 Definition & Scope
  • 8.2 Regional Market Share Analysis, 2021 & 2030
  • 8.3 Regional Market Snapshot
  • 8.4 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030
  • 8.5 North America
    • 8.5.1 North America Biosimulation Market Share Analysis, By Country, 2021
    • 8.5.2 U.S.
      • 8.5.2.1 U.S. Biosimulation Market, 2017 - 2030 (USD Million)
    • 8.5.3 Canada
      • 8.5.3.1 Canada Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.6 Europe
    • 8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2021
    • 8.6.2 U.K.
      • 8.6.2.1 U.K. Biosimulation Market, 2017 - 2030 (USD Million)
    • 8.6.3 Germany
      • 8.6.3.1 Germany Biosimulation Market, 2017 - 2030 (USD Million)
    • 8.6.4 France
      • 8.6.4.1 France Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.7 Asia Pacific
    • 8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2021
    • 8.7.2 Japan
      • 8.7.2.1 Japan Biosimulation Market, 2017 - 2030 (USD Million)
    • 8.7.3 China
      • 8.7.3.1 China Biosimulation Market, 2017 - 2030 (USD million)
    • 8.7.4 India
      • 8.7.4.1 India Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.8 Latin America
    • 8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2021
    • 8.8.2 Brazil
      • 8.8.2.1 Brazil Biosimulation Market, 2017 - 2030 (USD Million)
    • 8.8.3 Mexico
      • 8.8.3.1 Mexico Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.9 MEA
    • 8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2021
    • 8.9.2 South Africa
      • 8.9.2.1 South Africa Biosimulation Market, 2017 - 2030 (USD Million)

Chapter 9 Biosimulation Market - Competitive Analysis

  • 9.1 Strategy Framework
  • 9.2 Market Participant Categorization
  • 9.3 Public Companies
    • 9.3.1 Company market position analysis
    • 9.3.2 Comparative analysis by product category
  • 9.4 Private Companies
    • 9.4.1 List of Private companies
    • 9.4.2 List of Emerging companies in the Asia Pacific Region

Chapter 10 Biosimulation Market - Company Profiles

  • 10.1 Certara, USA
    • 10.1.1 Company overview
    • 10.1.2 Financial performance
    • 10.1.3 Product benchmarking
    • 10.1.4 Strategic initiatives
  • 10.2 Simulations Plus
    • 10.2.1 Company overview
    • 10.2.2 Financial performance
    • 10.2.3 Product benchmarking
    • 10.2.4 Strategic initiatives
  • 10.3 Dassault Systemes
    • 10.3.1 Company overview
    • 10.3.2 Financial performance
    • 10.3.3 Product benchmarking
    • 10.3.4 Strategic initiatives
  • 10.4 Schrodinger, Inc.
    • 10.4.1 Company overview
    • 10.4.2 Financial performance
    • 10.4.3 Product benchmarking
    • 10.4.4 Strategic initiatives
  • 10.5 Advanced Chemistry Development
    • 10.5.1 Company overview
    • 10.5.2 Product benchmarking
    • 10.5.3 Strategic initiatives
  • 10.6 Chemical Computing Group ULC
    • 10.6.1 Company overview
    • 10.6.2 Financial performance
    • 10.6.3 Product benchmarking
    • 10.6.4 Strategic initiatives
  • 10.7 Physiomics Plc
    • 10.7.1 Company overview
    • 10.7.2 Financial performance
    • 10.7.3 Product benchmarking
    • 10.7.4 Strategic initiatives
  • 10.8 Rosa & Co. LLC
    • 10.8.1 Company overview
    • 10.8.2 Product benchmarking
    • 10.8.3 Strategic initiatives
  • 10.9 Biosimulation Consulting Inc.
    • 10.9.1 Company overview
    • 10.9.2 Financial performance
    • 10.9.3 Service benchmarking
  • 10.10 Genedata AG
    • 10.10.1 Company overview
    • 10.10.2 Financial performance
    • 10.10.3 Product benchmarking
    • 10.10.4 Strategic initiatives
  • 10.11 Instem Group of Companies
    • 10.11.1 Company overview
    • 10.11.2 Financial performance
    • 10.11.3 Product benchmarking
    • 10.11.4 Strategic initiatives
  • 10.12 PPD, Inc.
    • 10.12.1 Company overview
    • 10.12.2 Financial performance
    • 10.12.3 Service benchmarking
    • 10.12.4 Strategic initiatives
  • 10.13 Yokogawa Insilico Biotechnology GmbH
    • 10.13.1 Company overview
    • 10.13.2 Product benchmarking
    • 10.13.3 Strategic initiatives
  • 10.14 Immunetrics
    • 10.14.1 Company overview
    • 10.14.2 Product benchmarking

Chapter 11 KOL Commentary

Product Code: GVR-1-68038-051-4

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of products for major companies
  • Table 3 List of private companies
  • Table 4 List of emerging companies
  • Table 5 North America biosimulation market, by country, 2017 - 2030 (USD Million)
  • Table 6 North America biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 7 North America biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 8 North America biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 9 North America biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 10 U.S. biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 11 U.S. biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 12 U.S. biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 13 U.S. biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 14 Canada biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 15 Canada biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 16 Canada biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 17 Canada biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 18 Europe biosimulation market, by country, 2017 - 2030 (USD Million)
  • Table 19 Europe biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 20 Europe biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 21 Europe biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 22 Europe biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 23 Germany biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 24 Germany biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 25 Germany biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 26 Germany biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 27 U.K. biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 28 U.K. biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 29 U.K. biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 30 U.K. biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 31 France biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 32 France biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 33 France biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 34 France biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 35 Asia Pacific biosimulation market, by country, 2017 - 2030 (USD Million)
  • Table 36 Asia Pacific biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 37 Asia Pacific biosimulation services market, by type, 2017 - 2030(USD Million)
  • Table 38 Asia Pacific biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 39 Asia Pacific biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 40 Japan biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 41 Japan biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 42 Japan biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 43 Japan biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 44 China biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 45 China biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 46 China biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 47 China biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 48 India biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 49 India biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 50 India biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 51 India biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 52 Latin America biosimulation market, by country, 2017 - 2030 (USD Million)
  • Table 53 Latin America biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 54 Latin America biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 55 Latin America biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 56 Latin America biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 57 Brazil biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 58 Brazil biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 59 Brazil biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 60 Brazil biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 61 Mexico biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 62 Mexico biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 63 Mexico biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 64 Mexico biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 65 MEA biosimulation market, by country, 2017 - 2030 (USD Million)
  • Table 66 MEA biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 67 MEA biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 68 MEA biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 69 MEA biosimulation market, by end-use, 2017 - 2030 (USD Million)
  • Table 70 South Africa biosimulation market, by product, 2017 - 2030 (USD Million)
  • Table 71 South Africa biosimulation services market, by type, 2017 - 2030 (USD Million)
  • Table 72 South Africa biosimulation market, by application, 2017 - 2030 (USD Million)
  • Table 73 South Africa biosimulation market, by end-use, 2017 - 2030 (USD Million)

List of Figures

  • Fig. 1 Biosimulation market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity Flow Analysis
  • Fig. 9 Biosimulation Market outlook (2021, USD Million)
  • Fig. 10 Biosimulation market segmentation and scope
  • Fig. 11 Biosimulation market dynamics analysis
  • Fig. 12 Biosimulation market driver and restraints impact analysis
  • Fig. 13 Biosimulation market driver analysis
  • Fig. 14 Biosimulation market drivers impact analysis
  • Fig. 15 R&D expenditures by various market players in 2021 (USD Million)
  • Fig. 16 Biosimulation market restraint impact
  • Fig. 17 Biosimulation market restraint impact analysis
  • Fig. 18 Penetration & growth prospect mapping
  • Fig. 19 COVID-19 new cases in major 35 countries around the world
  • Fig. 20 Biosimulation market: Product movement analysis
  • Fig. 21 Biosimulation market product outlook: Key takeaways
  • Fig. 22 Software market, 2017 - 2030 (USD Million)
  • Fig. 23 Services market, 2017 - 2030 (USD Million)
  • Fig. 24 In-house Services market, 2017 - 2030 (USD Million)
  • Fig. 25 Contract Services market, 2017 - 2030 (USD Million)
  • Fig. 26 Biosimulation market: Application movement analysis
  • Fig. 27 Biosimulation market application outlook: Key takeaways
  • Fig. 28 Drug development market, 2017 - 2030 (USD Million)
  • Fig. 29 Drug discovery market, 2017 - 2030 (USD Million)
  • Fig. 30 Others market, 2017 - 2030 (USD Million)
  • Fig. 31 Biosimulation market: End-use movement analysis
  • Fig. 32 Biosimulation market end-use outlook: Key takeaways
  • Fig. 33 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
  • Fig. 34 CROs market, 2017 - 2030 (USD Million)
  • Fig. 35 Regulatory authorities market, 2017 - 2030 (USD Million)
  • Fig. 36 Academic research institutions market, 2017 - 2030 (USD Million)
  • Fig. 37 Regional outlook, 2021 & 2030
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America Biosimulation market share, by country, 2021
  • Fig. 40 U.S. biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 41 Canada biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 42 Europe biosimulation market share analysis, by country, 2021
  • Fig. 43 U.K. Biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 44 Germany biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 45 France biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 46 Asia Pacific biosimulation market share analysis, by country, 2021
  • Fig. 47 Japan biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 48 China biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 49 India biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 50 Latin America Biosimulation market share analysis, by country, 2021
  • Fig. 51 Brazil biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 52 Mexico Biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 53 MEA biosimulation market share analysis, by country, 2021
  • Fig. 54 South Africa biosimulation market, 2017 - 2030 (USD Million)
  • Fig. 55 Strategy framework
  • Fig. 56 Market participant categorization
  • Fig. 57 Biosimulation: Heat Map Analysis
  • Fig. 58 Biosimulation market: Application-wise product ranking
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!